July 25, 2018 6:06pm

In the race of distance in the sector closing positive as markets took-off at the close

Earnings (LPS or loss-per-share) are about to start which validates the shaky pricing

 

Gene editing stocks stayed in the toilet for yet another session… CRSP (-$0.99 or -1.91%), EDIT (-$0.64 or -1.97%) and NTLA (-$0.28 or -0.98%).

 

Pre-open indications: 5 hits and 3 miss

 

I say today what others won’t, so you can do what others can’t!

Never leave an investor uninformed!  Want to know WHY, WHAT and HOW, subscribe!

Henry’omics:

 

The sector is suffering snail’s pace growth; again it’s a momentum that has caused suffering.

There is still a lot of risk in the sector as we approach “earnings” or LPS (loss-per-share) season.

Sentiment is missing the beat as trading is the motivator of upside moves; and I hope to see more?

 

The advance/decline line scenario of 45 covered companies:   

  • The open was positive with an A/DL of 27/16 and 2 flats;
  • The mid-day continued positive with an A/DL of 25/19 and 1 flat;
  • The close was positive with an A/DL of 24/16 and 5 flat;

 

Pre-open indications: 5 hit and 3 miss

  • bluebird bio (BLUE) closed up +$8.85 – miss;
  • Caladrius Biosciences (CLBS) closed up +$0.23 – miss;
  • Crispr (CRSP) closed down -$0.99 – hit;
  • Editas (EDIT) closed down -$0.64 – hit;
  • Fate Therapeutics (FATE) closed down -$0.46 – miss;
  • Intellia (NTLA) closed down -$0.28 – hit;
  • Regenxbio (RGNX) closed up +$1.40 – hit;
  • Verastem Oncology (VSTM) closed down -$0.08 – hit;

 

Of the 45 companies covered on Wednesday; 16 downside equities finished in a range of -$0.03 (HSGX) to -$4.69 (SAGE) while the 24 upside equities oscillated from +$0.01 (BCLI) to $8.85 (BLUE) with 5 flat closes.

 

From the pre-open newsletter titled, “is it time? The oversold are drooping on the vine and I still believe it’s a picking period. I will always take the “hit” for being early in my forecasts.”

I also stated, “Be'in a drinkin' man, it might be time to pick the oversold grapes otherwise there isn't any wine for frivolity!”

 

Biostage (BSTG) is living-up to its reputation of ripping-off investors – another downside slide of -$0.52 or -13.51% to $3.33 – my OPINION!

 

The pain continues for the three (3) mentioned gene "editors" ...

 

Review the mid-day review of gene editing pricings: Gene editing stocks are a game of pick-up-stick’s trading targets … https://www.regmedinvestors.com/articles/10412

Wednesday: CRSPR stocks stayed in the downside for yet another session… CRSP (-$0.99 or -1.91%), EDIT (-$0.64 or -1.97%) and NTLA (-$0.28 or -0.98%). As I had stated in the mid-day, “Have “bottoms” been declared – not in their current DNA? Maintaining SELL as there is more historical upside to ‘eat’ through.”

Tuesday: CRSPR stocks stayed in the tank in yet another session… CRSP (-$5.46 or -9.53%), EDIT (-$2.91 or -8.23%) and NTLA (-$1.96 or -6.44%). Another “shuffle” to the downside as I had stated, “it ain’t over as it falls precipitously in the day’s range!”

Monday: the hits just kept coming as the gene “editors” downside drift continues:  CRISPR Therapeutics (CRSP -$1.08 or -1.85%); Editas Medicine (EDIT -$0.88 or -2.23%) and Intellia Therapeutics (NTLA -$1.17 or -3.70%) … investors are speaking to negative trust of researchers!

Friday: follow the bouncing share pricing, a session of speculation to the downside: CRISPR Therapeutics (CRSP -$0.04 or +0.07%); Editas Medicine (EDIT +$0.12 or +0.33%) and Intellia Therapeutics (NTLA -$0.01 or -0.03%) …

Last Thursday for gene editing companies was a day of “rhyme or reason” with the oversold getting yet again ready to be overbought again as trading speciation controlled the session: CRISPR Therapeutics (CRSP +$0.21 or +0.36%) stayed down for the count; Editas Medicine (EDIT +$0.75 or +2.12%) and Intellia Therapeutics (NTLA +$0.63 or +2.03%) … flew close to the flatlands to not melt their upside (the Icarus story) after …

The previous Wednesday, what has speculation born: gene editing stocks dumped: Editas Medicine (EDIT -$1.08 or -2.96%), CRISPR Therapeutics (CRSP -$3.48 or -5.61%) and Intellia Therapeutics (NTLA -$0.36 or -1.15%) …

The previous Tuesday, gene editing stocks high jumped in response to their dramatic decline: Editas Medicine (EDIT +$1.26 or +3.58%), CRISPR Therapeutics (CRSP +$1.95 or +3.25%) and Intellia Therapeutics (NTLA +$2.00 or +6.81%) …

The previous Monday, gene editing stocks dropped like stones in a lake: Editas Medicine (EDIT -$2.70 or -7.21%), CRISPR Therapeutics AG (CRSP -$5.65 or -8.60%) and Intellia Therapeutics (NTLA -$3.24 or -9.94%).

 

MY working trend (5 largest) lines:

… The greatest volume to the downside:  CRSP, BLCM, EDIT, VSTM and VCEL

… Upside volume was weighted to:  MDXG, SGMO, BLUE, GBT and BMRN

… Biggest $ downside: SAGE (-$4.69), SLDB (-$1.35), CRSP (-$0.99), BLCM (-$0.59) and EDIT (-$0.64)

 … Best moves to the $ upside: BLUE (+$8.85), ALNY (+$3.08), GBT (+$2.65), RARE (+$2.12) and RGNX (+$1.40)

… Flats:  KOOL, ONVO, OSIR, RENE.L and PSTI

 

The weekly count - decliners versus gainers – looks at the view from different angles:

……. look at the differences in decliners:

  • Wednesday’s decliners ranged from -0.06% < ONCE -$0.05> to -13.51% <BSTG -$0.52 > in 16 equities;
  • Tuesday’s decliners ranged from -0.22% <KOOL -$0.009 > to -10.44% <FATE -$1.14 > in 40 equities;
  • Monday’s decliners ranged from -0.21% <SAGE -$0.36 > to -6.82% <SLDB -$2.94 > in xx equities;
  • Friday’s decliners ranged from -0.03% <NTLA (-$0.01 > to -6.97% < MDXG -$0.28> in 24 equities;
  • Thursday’s decliners ranged from -0.24% < CRSP -$0.14> to -3.83% <ONCE -$3.27 > in 14 equities;
  • Last Wednesday’s decliners ranged from -0.13% <RGNX -$0.10 > to -8.59% <VYGR -$1.71 > in 30 equities;

Versus

… Look at the percentage’s (%) and spreads …

  • Wednesday’s gainers ranged from +0.23% <BCLI +$0.01 > to +9.62% <MDXG +$0.38 > in 24 equities;
  • Tuesday’s gainers ranged from +1.71% <IONS +$0.76 > to +4.40% < BCLI +$0.18> in 4 equities;
  • Monday’s gainers ranged from +0.46% <FATE +$0.05 > to +18.8% <CUR +$0.22> in 18 equities;
  • Friday’s gainers ranged from +0.10% <OSIR +$0.01 > to +4.12% <BLFS +$0.87 > in 15 equities;
  • Thursday’s gainers ranged from +0.18% <BMRN +$0.18 > to +21.68% <BSTG +$0.70 > in 30 equities;
  • Last Wednesday’s gainers ranged from +0.14% <KOOL+$0.0006> to +4.13% <BTX +$0.095 > in 13 equities;

 

Daily analytics and metrics:

  • The Dow traded 150 points higher after falling more than 100 points;
  • The Nasdaq Composite jumped 1% to an all-time high;
  • The S&P 500 gained 0.7%

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market:

  • Wednesday traded at 12.29, down -0.12%
  • Tuesday traded at 12.41, down -1.66%
  • Monday traded at 12.62, down -1.87%
  • Friday traded at 12.83, down -0.31%
  • Thursday traded at 12.87, up +6.36%
  • Last Wednesday traded at 11.94, down -1%

 

The iShares Russell 2000 (IWM) closed:

  • Wednesday was up +0.37%;
  • Tuesday was down -1.06%;
  • Monday was up +0.12%;
  • Friday was down -0.42%;
  • Thursday was up +0.68%;
  • Last Wednesday was up +0.28%;

 

The iShares NASDAQ Biotechnology (IBB) closed:

  • Wednesday was up +1.11%
  • Tuesday was down -0.14%
  • Monday was down -0.06 %
  • Friday was down -0.08%
  • Thursday was up +0.10%
  • Last Wednesday was down -0.09%

 

JULY sessions:

Wednesday closed POSITIVE with 16 decliners, 24 advancers and 5 flat;

Tuesday closed NEGATIVE with 40 decliners, 4 advancers and 1 flat;

Monday (7/23) closed NEGATIVE with 25 decliners, 18 advancers and 2 flats;

Friday closed NEGATIVE with 24 decliners, 15 advancers and 5 flats;

Thursday closed POSITIVE with 14 decliners, 28 advancers and 2 flats;

Wednesday closed NEGATIVE with 30 decliners, 13 advancers and 2 flat;

Tuesday closed POSITIVE with 13 decliners, 29 advancers and 3 flat;

Monday (7/16) closed NEGATIVE with 32 decliners, 10 advancers and 3 flat;

Friday closed POSITIVE with 17 decliners, 25 advancers and 3 flat;

Thursday closed POSITIVE with 19 decliners, 24 advancers and 2 flat;

Wednesday closed POSITIVE with 18 decliners, 24 advancers and 3 flat;

Tuesday closed NEGATIVE with 29 decliners, 15 advancers and 1 flat;

Monday (7/9) closed POSITIVE with 18 decliners, 22 advancers and 5 flat;

Friday closed POSITIVE with 8 decliners, 35 advancers and 2 flat;

Thursday closed POSITIVE with 18 decliners, 23 advancers and 4 flat;

Wednesday (7/4) was a holiday;

Tuesday closed POSITIVE with 9 decliners, 33 advancers and 3 flat;

Monday (7/2) closed POSITIVE with 15 decliners, 27 advancers and 3 flat;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.